Clearly, recent studies in delineating the vasoconstrictive properties of the AGT/renin/ACE/Ang II/AT1 receptor and the vasodilatory properties of the counteracting ACE2/Ang (1-7)/Mas receptor/AT2 receptor axes have greatly expanded the therapeutic targets available to treat hypertension and cardiovascular and kidney diseases. This evidence concerns the gene AGT and kidney disorder.